NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

NEO100 exceeded its prespecified six-month progression-free survival benchmark; pivotal-trial timing remains an analyst expectation.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) received new coverage from Roth Capital analyst Jonathan Aschoff in a report published September 24, 2026.

In August, NeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. Six-month progression-free survival was 48.9% against a prespecified 20% benchmark; median overall survival was 26.09 months. NeOnc plans to request an FDA Type B meeting to discuss a path toward registration. Roth expects an End-of-Phase 2 meeting in October and sees potential pivotal-trial starts before the end of 2026. Those dates are analyst expectations, not confirmed timelines.

NeOnc raised $15 million through a September registered direct offering priced at $4.20 per share, with accompanying warrants exercisable at $4.20. NEO212 Phase 1 work established a recommended Phase 2 dose of 610 mg after dose escalation reached its protocol-defined maximum tolerated dose.

Positive

• NEO100 six-month progression-free survival: 48.9% versus 20% prespecified benchmark
• NEO212 Phase 1: 610 mg recommended Phase 2 dose established

Negative

• None.

News Explained

NeOnc says it has redeemed its outstanding Series A convertible preferred stock; a September 17, 2026 company-news record reports that all outstanding shares were redeemed, eliminating the related potential dilution.

Sources and calculations

• NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst (2026-09-24)
• NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution (2026-09-17)

Key Figures

Six-month progression-free survival: 48.9% vs. 20% Median overall survival: 26.09 months Expected FDA Type B meeting: October +5 more

Six-month progression-free survival

48.9% vs. 20%

NEO100 Phase 2a results vs. prespecified benchmark

Median overall survival

26.09 months

NEO100 Phase 2a results

Expected FDA Type B meeting

October

Roth analyst expectation; not an FDA commitment

Potential pivotal-trial start

Before the end of 2026

Roth analyst expectation

Recommended Phase 2 dose

610 mg

NEO212 Phase 1 dose escalation

Registered direct offering

$15 million

September financing

Share price

$4.20 per share

September offering

Warrant exercise price

$4.20

Accompanying offering warrants

Historical Context

2 past events · Latest: Sep 22

2 events

1. Sep 22

   Clinical data

   24h Move

   +3.6%

   Reported Phase 2a NEO100 results, including six-month progression-free survival above the prespecified benchmark.

2. Sep 17

   Financing update

   24h Move

   +14.1%

   Reported a registered direct offering and cash redemption of outstanding Series A preferred stock.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

progression-free survival, type b meeting, registered direct offering, chemistry, manufacturing and controls, +1 more

5 terms

progression-free survival medical

"six-month progression-free survival of 48.9% versus a prespecified 20% benchmark"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

type b meeting regulatory

"request a Type B meeting with the FDA"

A Type B meeting is a formal, scheduled discussion between a drug or medical-device developer and a health regulator to resolve key mid‑ or late‑stage development issues such as clinical trial plans, interpretation of results, or steps needed for approval. Like a mid‑project review with an inspector, the meeting’s outcome can meaningfully change the timeline, cost and risk for a candidate: a clear, positive outcome lowers uncertainty for investors, while requests for more data or changes can signal delays and extra expense.

registered direct offering financial

"a $15 million registered direct offering in September"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

chemistry, manufacturing and controls regulatory

"FDA feedback on chemistry, manufacturing and controls in July"

Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.

convertible preferred stock financial

"redeeming its outstanding Series A convertible preferred stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24.

The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development.

The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produced six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported median overall survival of 26.09 months. The company said it planned to request a Type B meeting with the FDA to discuss a registrational path.

That puts regulatory interaction squarely in the spotlight. A September report summarizing Roth's research says Aschoff expects an FDA Type B End-of-Phase 2 meeting in October and sees potential pivotal-trial starts before the end of 2026. Those are analyst expectations, not FDA commitments or guaranteed timelines.

Roth's longer-range model reportedly envisions NEO100 launching in 2029 and NEO212 in 2030, assuming successful clinical development, regulatory approval, financing and commercialization. The two programs target difficult-to-treat central nervous system cancers, including recurrent high-grade astrocytoma, glioblastoma and brain metastases.

NEO212 is also moving forward. The company reported FDA feedback on chemistry, manufacturing and controls in July, while Phase 1 work established a recommended Phase 2 dose of 610 mg after dose escalation reached its protocol-defined maximum tolerated dose.

Meanwhile, NeOnc has strengthened its balance sheet for the next leg of development with a $15 million registered direct offering in September. The financing was priced at $4.20 per share, with accompanying warrants carrying a $4.20 exercise price. Roth Capital and A.G.P./Alliance Global Partners acted as placement agents.

The company also recently announced that executives purchased NeOnc shares in the open market following the NEO100 data, while separately redeeming its outstanding Series A convertible preferred stock.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeOnc report from its NEO100 Phase 2a study?

In August, NeOnc reported 48.9% six-month progression-free survival against a prespecified 20% benchmark in recurrent IDH1-mutant high-grade glioma. Reported median overall survival was 26.09 months.

When does Roth expect NeOnc's FDA meeting and potential pivotal trials?

Roth expects an FDA Type B End-of-Phase 2 meeting in October and sees potential pivotal-trial starts before the end of 2026. These are analyst expectations, not FDA commitments or guaranteed timelines.

What other share-related actions did NeOnc announce?

NeOnc announced that executives bought shares in the open market following the NEO100 data. The company separately redeemed its outstanding Series A convertible preferred stock.